Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Journal
Overview
publication venue for
-
Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.
2020
-
Guidelines for Cord Blood Unit Thaw and Infusion.
2020
-
Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 3: Focus on Cardiorespiratory Dysfunction, Infections, Liver Dysfunction, and Delirium.
2017
-
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.
2016
-
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
2015
-
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.
2015
-
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.
2015
-
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
2014
-
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
2009
-
Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease.
2008
-
Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program.
2006
-
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
2006
-
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.
2001
-
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma..
26.
2020
-
Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation..
26.
2020
-
Pretransplantation Cognitive Dysfunction in Advanced-Age Hematologic Cancers: Predictors and Associated Outcomes..
26.
2020
-
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma..
26.
2020
-
Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study..
26.
2020
-
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation..
26.
2020
-
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery..
26.
2020
-
Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation..
26.
2020
-
Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation..
26.
2020
-
Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies..
26.
2019
-
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease..
26.
2019
-
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma..
26.
2019
-
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation..
25.
2019
-
Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia..
25.
2019
-
Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation..
25.
2019
-
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)..
25.
2019
-
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement..
25.
2019
-
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation..
25.
2019
-
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation..
25.
2019
-
Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation..
25.
2019
-
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis..
25.
2019
-
Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study..
25.
2018
-
Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes..
25.
2018
-
Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation..
25.
2018
-
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes..
25.
2018
-
Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies..
25.
2018
-
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation..
25.
2018
-
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database..
25.
2018
-
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation..
25.
2018
-
CALIPSO: A Randomized Controlled Trial of Calfactant for Acute Lung Injury in Pediatric Stem Cell and Oncology Patients..
24.
2018
-
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation..
24.
2018
-
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes..
24.
2018
-
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant..
24.
2018
-
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation..
24.
2018
-
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study..
24.
2018
-
Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most..
24.
2018
-
Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection..
24.
2018
-
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma..
24.
2018
-
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation..
24.
2018
-
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials..
24.
2018
-
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome ..
24.
2018
-
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults..
24.
2017
-
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance..
24.
2017
-
Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation..
24.
2017
-
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis..
24.
2017
-
Burnout, Moral Distress, Work-Life Balance, and Career Satisfaction among Hematopoietic Cell Transplantation Professionals..
24.
2017
-
Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis..
24.
2017
-
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia..
24.
2017
-
Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices..
24.
2017
-
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation..
24.
2017
-
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation..
24.
2017
-
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation..
23.
2017
-
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies..
23.
2017
-
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies..
23.
2017
-
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies..
23.
2017
-
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia..
23.
2017
-
Real-World Economic Burden Associated with Transplantation-Related Complications..
23.
2017
-
Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34+ Selected Hematopoietic Cell Transplantation..
23.
2017
-
Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center..
23.
2017
-
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia..
23.
2017
-
Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes..
23.
2017
-
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation..
23.
2017
-
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma..
23.
2017
-
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study..
23.
2017
-
Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes..
23.
2017
-
Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection..
23.
2017
-
Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation..
23.
2017
-
Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors..
23.
2017
-
Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis..
23.
2016
-
Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response..
23.
2016
-
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study..
23.
2016
-
Safety and Efficacy of Granulocyte Colony-Stimulating Factor Monotherapy for Peripheral Blood Stem Cell Collection in POEMS Syndrome..
23.
2016
-
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation..
23.
2016
-
Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes..
23.
2016
-
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning..
23.
2016
-
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy..
22.
2016
-
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa..
22.
2016
-
Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation..
22.
2016
-
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis..
22.
2016
-
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes..
22.
2016
-
DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center..
22.
2016
-
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning..
22.
2016
-
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation..
22.
2016
-
Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation..
22.
2015
-
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation..
22.
2015
-
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation..
22.
2015
-
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors..
22.
2015
-
Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum..
21.
2015
-
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma..
22.
2015
-
In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children..
21.
2015
-
Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact..
22.
2015
-
Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies..
21.
2015
-
Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis..
22.
2015
-
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia..
21.
2015
-
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma..
21.
2015
-
Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation..
21.
2015
-
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse..
21.
2015
-
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation..
21.
2015
-
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia..
21.
2015
-
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen..
21.
2015
-
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease..
21.
2015
-
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation..
21.
2015
-
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation..
21.
2015
-
Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma..
21.
2014
-
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation..
21.
2014
-
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma..
20.
2014
-
Older patients with myeloma derive similar benefit from autologous transplantation..
20.
2014
-
Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027..
20.
2014
-
Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome..
20.
2014
-
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation..
20.
2014
-
A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation..
20.
2014
-
Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T Cell-depleted peripheral blood and cord blood stem cell transplantations..
20.
2014
-
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation..
20.
2014
-
Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival..
20.
2014
-
Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol..
20.
2014
-
Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin..
20.
2014
-
Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation..
20.
2014
-
Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group report..
20.
2014
-
Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies..
20.
2014
-
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia..
20.
2014
-
"No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment..
20.
2013
-
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients..
20.
2013
-
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research..
20.
2013
-
Prevalence of hematopoietic cell transplant survivors in the United States..
19.
2013
-
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma..
19.
2013
-
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia..
19.
2013
-
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration..
19.
2013
-
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission..
19.
2013
-
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma..
19.
2013
-
A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation..
19.
2013
-
Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects..
19.
2013
-
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match..
19.
2013
-
Salvage second hematopoietic cell transplantation in myeloma..
19.
2013
-
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study..
19.
2012
-
Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients..
19.
2012
-
Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution..
19.
2012
-
Immune recovery after allogeneic hematopoietic stem cell transplantation: is it time to revisit how patients are monitored?.
18.
2012
-
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease..
19.
2012
-
Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield..
18.
2012
-
Second stem cell transplants for multiple myeloma. If at once you don't succeed, should we really try, try again?.
18.
2012
-
The use of back-up units to enhance the safety of unrelated donor cord blood transplantation..
18.
2012
-
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure..
18.
2011
-
Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia..
18.
2011
-
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation..
18.
2011
-
Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients..
18.
2011
-
Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303..
18.
2011
-
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes..
18.
2011
-
Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation..
18.
2011
-
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study..
18.
2011
-
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib..
17.
2011
-
Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome..
17.
2011
-
Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT)..
17.
2011
-
Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study..
17.
2011
-
Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin..
17.
2011
-
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life..
17.
2011
-
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303..
17.
2011
-
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation..
17.
2011
-
T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies..
17.
2011
-
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee..
17.
2011
-
Retrospective outcome data for hematopoietic stem cell transplantation in patients with concurrent coronary artery disease..
17.
2010
-
Unrelated donor transplantation for acute myelogenous leukemia in first remission..
17.
2010
-
Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities..
16.
2010
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation..
16.
2010
-
Regulatory T cell content in the bone marrow graft does not predict the occurrence of acute GVHD..
17.
2010
-
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease..
17.
2010
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes..
16.
2010
-
The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients..
16.
2010
-
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science..
16.
2010
-
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma..
16.
2010
-
Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation..
16.
2010
-
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction..
16.
2010
-
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation..
16.
2010
-
Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation..
16.
2010
-
Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation..
16.
2009
-
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma..
15.
2009
-
Outcome of transplantation for myelofibrosis..
16.
2009
-
Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease..
16.
2009
-
Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation..
16.
2009
-
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR..
16.
2009
-
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease..
15.
2009
-
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation..
15.
2009
-
Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization..
15.
2009
-
Defining the intensity of conditioning regimens: working definitions..
15.
2009
-
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia..
15.
2009
-
Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction..
15.
2009
-
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts..
15.
2009
-
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation..
15.
2009
-
Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation..
15.
2009
-
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants..
15.
2009
-
Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma..
15.
2009
-
Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors..
15.
2009
-
Toll-like receptor 4 polymorphisms and risk of gram-negative bacteremia after allogeneic stem cell transplantation. A prospective pilot study..
15.
2009
-
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes..
15.
2009
-
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma..
15.
2009
-
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes..
15.
2009
-
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma..
15.
2009
-
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial..
14.
2008
-
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR)..
14.
2008
-
Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study..
14.
2008
-
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation..
14.
2008
-
Comparison of twin and autologous transplants for multiple myeloma..
14.
2008
-
Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)..
14.
2008
-
Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis..
14.
2008
-
Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options..
14.
2008
-
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant..
14.
2008
-
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma..
14.
2008
-
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS..
14.
2008
-
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors..
14.
2008
-
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings..
14.
2008
-
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning..
14.
2008
-
Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease..
14.
2008
-
Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease..
13.
2007
-
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure..
13.
2007
-
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant..
13.
2007
-
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program..
13.
2007
-
Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant..
13.
2007
-
Hematopoietic progenitor cell transplantation in 2007: new challenges and new opportunities for the center for international blood and marrow transplant research..
13.
2007
-
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes..
13.
2007
-
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan..
13.
2007
-
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment..
13.
2007
-
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies..
13.
2007
-
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation..
12.
2006
-
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy..
12.
2006
-
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia..
12.
2006
-
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy..
12.
2006
-
The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial)..
12.
2006
-
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation..
12.
2006
-
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities..
11.
2005
-
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation..
11.
2005
-
Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model..
10.
2004
-
An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting..
10.
2004
-
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma..
10.
2004
-
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation..
10.
2004
-
Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission..
10.
2004
-
Robert Alan Good, MD, PhD..
9.
2003
-
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel..
9.
2003
-
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes..
8.
2002
-
The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation..
8.
2002
-
Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization..
8.
2002
-
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation..
7.
2001
-
Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients..
6.
2000
-
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1..
6.
2000
-
HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci..
5.
1999
-
Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma..
5.
1999
-
Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy..
5.
1999
-
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients..
3.
1997
-
Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis..
3.
1997
-
The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation..
3.
1997
-
Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation..
3.
1997
-
The 2008 education supplement on hematopoietic stem cell transplantation..
14.
2008
-
An Old Friend Is Trouble for Double-Expressor and Double-Hit Lymphoma.
2018
-
Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.
2016
-
Persistent problems with persistent disease: minimal residual disease in acute myelogenous leukemia.
2013
-
Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".
2020
-
Regarding "Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study".
2019
-
Reply.
2019
-
Analysis of Cyclosporine A Levels Supports New Dosing Guidelines in Adult Double-Unit Cord Blood Transplant Recipients to Optimize Immunosuppression Early Post-Transplant.
2016
-
Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation.
2016
-
Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients.
2006
-
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
2004
-
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
2018
-
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.
2016
-
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.
2016
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
2015
-
Blood and marrow transplant clinical trials network state of the Science Symposium 2014.
2014
-
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
2013
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
2013
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.
2013
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
2013
-
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
2010
-
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
2009
-
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.
2007
-
Clinical trials of hematopoietic cell transplantations: current needs and future strategies.
2000
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction..
19.
2013
-
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation..
16.
2010
-
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
2020
-
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
2019
-
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
2019
-
Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond.
2019
-
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
2018
-
Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.
2018
-
The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.
2018
-
Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation.
2017
-
Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.
2017
-
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
2016
-
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
2016
-
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
2016
-
Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
2016
-
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
2016
-
Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.
2015
-
Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
2015
-
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
2015
-
Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations.
2015
-
Guidelines for defining and implementing standard episode of care for hematopoietic stem cell transplantation within the context of clinical trials.
2015
-
Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.
2012
-
Enhancing immune reconstitution: from bench to bedside.
2012
-
Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells.
2012
-
Pretransplantation assessments and symptom profiles: predicting transplantation-related toxicity and improving patient-centered outcomes.
2011
-
What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
2011
-
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).
2010
-
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
2010
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
2010
-
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
2010
-
Relapse after allogeneic hematopoietic cell therapy.
2009
-
Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy.
2009
-
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
2009
-
Allografting older patients--myths and realities.
2009
-
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
2009
-
In utero hematopoietic stem cell transplantation: progress toward clinical application.
2008
-
Clinical strategies to enhance posttransplant immune reconstitution.
2008
-
Dendritic cells in transplantation and immune-based therapies.
2007
-
Advances in biology, diagnostics, and treatment of Hodgkin's disease.
2006
-
Immune responses to Aspergillus fumigatus infections.
2006
-
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
2005
-
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
2003
Identity
ISO Abbreviation
-
Biol Blood Marrow Transplant
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)